The importance of low visfatin values in osteoid osteoma patient: a prospective study

Basit Öğe Kaydı
dc.authorid0000-0003-2149-8154en_US
dc.contributor.authorUlus, Sait Anıl
dc.contributor.authorÖzkul, Emin
dc.date.accessioned2024-01-17T12:39:25Z
dc.date.available2024-01-17T12:39:25Z
dc.date.issued2023en_US
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Ortopedi ve Travmatoloji Ana Bilim Dalıen_US
dc.description.abstractAbstract. – OBJECTIVE: Visfatin is currently a cytokine that is extensively researched in the field of bone diseases. In this prospective study, we aimed to investigate the potential of serum visfatin levels as a biomarker for the diagnosis of osteoid osteoma. PATIENTS AND METHODS: This study included a cohort of 20 patients diagnosed with osteoid osteoma (Group 1) and 30 healthy individuals (Group 2). The age, gender, cyst sizes, and visfatin values of all participants were documented and analyzed. RESULTS: There was a significant difference in visfatin levels between the two groups. The median visfatin level in Group 1 was 6.13 ng/ml (IQR: 4.21-8.08), while in Group 2, it was 15.83 ng/ml (IQR: 11.11-20.6). The difference was statistically significant (p<0.000). The optimal cutoff value for visfatin was found to be 7.74 ng/ml, which had a 93% sensitivity and 78% specificity. An area under the curve of receiver operating characteristic (ROC) analysis of 0.85 indicates good diagnostic performance. CONCLUSIONS: Our study revealed a significant decrease in visfatin levels among patients diagnosed with osteoid osteomas in comparison to the healthy control group. The ROC analysis revealed that visfatin exhibited a commendable diagnostic capacity, indicating its potential utility as a biomarker for osteoid osteoma.en_US
dc.identifier.citationUlus, S. A. ve Özkul, E. (2023). The importance of low visfatin values in osteoid osteoma patient: a prospective study. European Review for Medical and Pharmacological Sciences, 27(23), 11543-11549.en_US
dc.identifier.doi10.26355/eurrev_202312_34592
dc.identifier.endpage11549en_US
dc.identifier.issn1128-3602
dc.identifier.issue23en_US
dc.identifier.pmid38095401
dc.identifier.scopus2-s2.0-85179770168
dc.identifier.scopusqualityQ2
dc.identifier.startpage11543en_US
dc.identifier.urihttps://www.europeanreview.org/wp/wp-content/uploads/11543-11549.pdf
dc.identifier.urihttps://hdl.handle.net/11468/13211
dc.identifier.volume27en_US
dc.identifier.wosWOS:001159390600005
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorUlus, Sait Anıl
dc.institutionauthorÖzkul, Emin
dc.language.isoenen_US
dc.publisherVerduci Editore s.r.len_US
dc.relation.ispartofEuropean Review for Medical and Pharmacological Sciences
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectVisfatinen_US
dc.subjectOsteoid osteomaen_US
dc.subjectBiomarkeren_US
dc.titleThe importance of low visfatin values in osteoid osteoma patient: a prospective studyen_US
dc.titleThe importance of low visfatin values in osteoid osteoma patient: a prospective study
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
The importance of low visfatin values in osteoid osteoma patient.pdf
Boyut:
396.17 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Cerrahi Tıp Bilimleri Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu